

Name: Angelo Paradiso

Group (University, Country): Istituto Tumori G paolo II Bari, Experimental Oncology, Institutional Biobank

E-mail address: a.paradiso@oncologico.bari.it; biobanca@oncologico.bari.it

General research subject: risk biomarkers; predictive biomarkers

Group website: www.oncologico.bari.it

Publications (20 most recent):

1: Schirosi L, De Summa S, Tommasi S, Paradiso A, Gasparini G, Popescu O, Simone G, Mangia A. VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients. *Int J Cancer*. 2017 Nov 1;141(9):1901-1911. doi: 10.1002/ijc.30868.

2: Simone G, Diotaiuti S, Digennaro M, Sambiasi D, De Summa S, Tommasi S, Altieri R, Mangia A, Dantona C, Paradiso A. Comment on 'Renewed interest in the progesterone receptor in breast cancer'. *Br J Cancer*. 2017 Jul 11;117(2):e1. doi: 10.1038/bjc.2017.90. Epub 2017 Apr 11.

3: Zotti P, Cocchi S, Polesel J, Cipolat Mis C, Bragatto D, Cavuto S, Conficconi A, Costanzo C, De Giorgi M, Drace CA, Fiorini F, Gangeri L, Lisi A, Martino R, Mosconi P, Paradiso A, Ravaioli V, Truccolo I, De Paoli P; ICPEG. Cross-cultural validation of health literacy measurement tools in Italian oncology patients. *BMC Health Serv Res*. 2017 Jun 19;17(1):410. doi: 10.1186/s12913-017-2359-0.

4: Digennaro M, Sambiasi D, Tommasi S, Pilato B, Diotaiuti S, Kardhashi A, Trojano G, Tufaro A, Paradiso AV. Hereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites. *Hered Cancer Clin Pract*. 2017 May 25;15:7. doi: 10.1186/s13053-017-0067-8. eCollection 2017.

5: Paradiso A, Singer CF. Therapeutic Strategies in Triple-Negative Breast Cancer. *Breast Care (Basel)*. 2017 Mar;12(1):6-7. doi: 10.1159/000460238. Epub 2017 Feb 28.

6: Braicu C, Chiorean R, Irimie A, Chira S, Tomuleasa C, Neagoe E, Paradiso A, Achimas-Cadariu P, Lazar V, Berindan-Neagoe I. Novel insight into triple-negative

breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy. *Expert Rev Mol Med*. 2016 Nov 7;18:e18. Review.

7: Pilato B, Pinto R, De Summa S, Petriella D, Lacalamita R, Danza K, Paradiso A, Tommasi S. BRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report. *Genes Chromosomes Cancer*. 2016 Oct;55(10):803-13. doi: 10.1002/gcc.22383. Epub 2016 Jul 4.

8: Paradiso AV, Digennaro M, Sambiasi D. Comment on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study'. *Br J Cancer*. 2016 Aug 23;115(5):e3. doi: 10.1038/bjc.2016.224. Epub 2016 Jul 26.

9: Gennari A, Amadori D, Scarpi E, Farolfi A, Paradiso A, Mangia A, Biglia N, Gianni L, Tienghi A, Rocca A, Maltoni R, Antonucci G, Bruzzi P, Nanni O. Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. *Breast Cancer Res Treat*. 2016 Aug;159(1):79-86.

10: Centomani I, Sgobba A, D'Addabbo P, Dipierro N, Paradiso A, De Gara L, Dipierro S, Viggiano L, de Pinto MC. Involvement of DNA methylation in the control of cell growth during heat stress in tobacco BY-2 cells. *Protoplasma*. 2015 Nov;252(6):1451-9.

11: Schirosi L, De Summa S, Tommasi S, Paradiso A, Sambiasi D, Popescu O, Simone G, Mangia A. Immunoprofile from tissue microarrays to stratify familial breast cancer patients. *Oncotarget*. 2015 Sep 29;6(29):27865-79. doi: 10.18632/oncotarget.4720.

12: Farolfi A, Scarpi E, Rocca A, Mangia A, Biglia N, Gianni L, Tienghi A, Valerio MR, Gasparini G, Amaducci L, Faedi M, Baldini E, Rubagotti A, Maltoni R, Paradiso A, Amadori D. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. *Eur J Cancer*. 2015 Sep;51(14):1874-81.

13: Cipolat Mis C, Truccolo I, Ravaioli V, Cocchi S, Gangeri L, Mosconi P, Drace C, Pomicino L, Paradiso A, De Paoli P; Italian Cancer Patient Education Group. Making patient centered care a reality: a survey of patient educational programs in Italian Cancer Research and Care Institutes. *BMC Health Serv Res*. 2015 Jul 30;15:298. doi: 10.1186/s12913-015-0962-5.

14: Horgan D, Paradiso A, McVie G, Banks I, Van der Wal T, Brand A, Lawler M. Is precision medicine the route to a healthy world? *Lancet*. 2015 Jul 25;386(9991):336-7.

- 15: Bellizzi A, Greco MR, Rubino R, Paradiso A, Forciniti S, Zeeberg K, Cardone RA, Reshkin SJ. The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells. *Int J Oncol.* 2015 Mar;46(3):1214-24.
- 16: De Pascalis I, Pilato B, Mazzotta A, Dell'Endice TS, Rubini V, Simone G, Paradiso A, Aiello V, Mangia A. Sister chromatid exchange: A possible approach to characterize familial breast cancer patients. *Oncol Rep.* 2015 Feb;33(2):930-4.
- 17: Oberst S, Boomsma F, Lombardo C, Docter M, Blaauwgeers H, De Paoli P, de Valeriola D, Paradiso A, Saghatchian M. Participation of Italian Cancer Centres of the Alleanza Contro Il Cancro (ACC) in the Organisation of European Cancer Institutes (OEI) Accreditation and Designation program: a successful first national initiative. *Tumori.* 2015;101 Suppl 1:S6-9.
- 18: Lacalamita R, Quaranta A, Trisorio Liuzzi MP, Nigro A, Simonetti U, Schirone M, Aloè F, Capochiani G, De Francesco G, Gadaleta C, Galetta D, Grammatica L, Guarini A, Mattioli V, Milella P, Moschetta A, Nardulli P, Nigro V, Silvestris N, Paradiso A. The European accreditation of Istituto Tumori Giovanni Paolo II of Bari. *Tumori.* 2015;101 Suppl 1:S14-8.
- 19: Paradiso A, Belardelli F. Application of OEI accreditation program to cancer institutes of the Alleanza Contro il Cancro Italian Network: a special project supported by the Italian Ministry of Health. *Tumori.* 2015;101 Suppl 1:S2-5.
- 20: Xu JM, Liu XJ, Ge FJ, Lin L, Wang Y, Sharma MR, Liu ZY, Tommasi S, Paradiso A. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. *J Exp Clin Cancer Res.* 2014 Dec 10;33:104. doi: 10.1186/s13046-014-0104-7.